Clinical Trial Update: Carbidopa/Levodopa Versus Carbidopa/Levodopa/Entacapone on Markers of Event Related Potentials (ERPs) in Patients With Idiopathic Parkinson's Disease (PD) and End-of-dose Wearing Off [Phase 4]

View source ↗

Summary

A Phase 4 trial comparing carbidopa/levodopa with and without entacapone in Parkinson's disease was withdrawn; no results are available.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• SINEMET (carbidopa and levodopa)
• Stalevo (levodopa;carbidopa;entacapone)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Parkinson's Disease | Phase 4 | Status: WITHDRAWN